

Rolf Classon proposed as new Chairman of BICO Group AB (publ)

The Nomination Committee of BICO Group AB (publ) proposes Rolf Classon as the new Chairman of the Board.

The Nomination Committee of BICO Group AB today announces the proposal of Rolf Classon to the Annual General Meeting as the company's new Chairman of the Board. Rolf Classon has been a board member of BICO Group AB since April 2022. Rolf Classon is a seasoned leader in the healthcare industry, having held numerous high-ranking positions in life science companies throughout the years. He currently serves as Vice Chairman of the Supervisory Board of Fresenius Medical Care AG & Co. KGaA, Chairman of Hill-Rom Holdings Inc., as well as a member of the Board of Directors of Catalent Inc. Throughout his career, Mr. Classon has served as Chairman of the Board of Directors in Tecan Group Ltd., Swedish Orphan International, and Chairman of the Executive Committee of Bayer HealthCare AG, and member of the Board of Directors for Millipore Corporation.

The present Chairman of the Board, Carsten Browall, has declined re-election at the 2023 Annual General Meeting.

"We are very pleased to propose Rolf Classon as the new Chairman of the Board at BICO Group. We also want to take this opportunity to thank Carsten Browall for his foremost work for the Board of Directors and BICO's growth journey since 2018."

Malin Björkmo, Chairman of the Nomination Committee, BICO Group AB

The Nomination Committee will present its complete proposal and reasoned statement in connection with the invitation to the 2023 annual general meeting.

For more information please contact:

Malin Björkmo, Chairman of the Nomination Committee

Mobile phone: +46 705-88 99 63

Email: malin@bjorkmoadvisors.se

Åsa Hillsten, Senior Advisor Investor Relations, BICO Group AB

Phone: +46 70-081 81 17

Email: ash@bico.com

PRESS RELEASE

03 February 2023 19:10:00 CET

**About BICO**

BICO is a leading provider of life science solutions and laboratory automation that enable more efficient development of new treatments with more specificity and less need for animal testing.

The company uses bioconvergence as its operating system, combining advanced technologies with biology to streamline and automate workflows within the pharmaceutical and biopharma industries.

With 32,000+ instruments installed in over 65 countries, BICO products and solutions are found in more than 3,500 laboratories, including the world's top 20 pharmaceutical companies, and have been cited in over 11,000 publications.

Operating through three business areas – Bioprinting, Biosciences and Bioautomation – the BICO Group strives towards the long-term ambition of enabling the reduction the world's organ shortage and speeding up drug development to create the future of life-saving treatments.

BICO is listed on Mid-Cap, Nasdaq Stockholm under BICO. www.bico.com

Attachments

[Rolf Classon proposed as new Chairman of BICO Group AB \(publ\)](#)